Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins

A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins

2000 • 1,723 citations

Mammalian ABC Transporters in Health and Disease

2002 • 1,531 citations

Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance

1999 • 796 citations

MRP3, an organic anion transporter able to transport anti-cancer drugs

1999 • 639 citations

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

1999 • 475 citations

The Leukotriene LTD4 Receptor Antagonist Mk571 Specifically Modulates MRP Associated Multidrug Resistance

1995 • 402 citations

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

2002 • 365 citations

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

1999 • 353 citations

Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4)

2003 • 301 citations

Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D₄ receptor antagonist

1989 • 266 citations

Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

1999 • 259 citations

Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)

2001 • 255 citations

A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells.

1997 • 249 citations

Pharmacogenetics and cancer therapy

2001 • 247 citations

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

2001 • 237 citations

Transport of amphipathic anions by human multidrug resistance protein 3.

2000 • 237 citations

Analysis of the MRP4 Drug Resistance Profile in Transfected NIH3T3 Cells

2000 • 227 citations

Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

2000 • 206 citations

Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

2000 • 196 citations

Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer Cells

2001 • 188 citations

Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.

2000 • 176 citations

Coordinated Action of Glutathione S-Transferases (GSTs) and Multidrug Resistance Protein 1 (MRP1) in Antineoplastic Drug Detoxification

1998 • 136 citations

ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.

1999 • 134 citations

Induction of Cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but Not of CYP2C9, CYP2C19, Multidrug Resistance (MDR-1) and Multidrug Resistance Associated Protein (MRP-1) by Prototypical Inducers in Human Hepatocytes

2000 • 114 citations

Role of Multidrug Resistance Protein 1 (MRP1) and Glutathione S-Transferase A1-1 in Alkylating Agent Resistance

2001 • 106 citations

CPT-11 in gastrointestinal cancer

1999 • 97 citations

Differential expression of sphingolipids in MRP1 overexpressing HT29 cells

2000 • 92 citations

Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in Caco-2 cells

2000 • 86 citations

Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.

1999 • 84 citations

New directions in the treatment of colorectal cancer

2000 • 79 citations

Transepithelial transport of vinblastine by kidney-derived cell lines. Application of a new kinetic model to estimate in situ Km of the pump

1990 • 77 citations

Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells

2000 • 71 citations

Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.

1986 • 68 citations

Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by nonsmall cell lung tumor cells in culture and its relationship to cell survival

1986 • 66 citations

pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

1999 • 66 citations

Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.

2000 • 63 citations

Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.

1992 • 57 citations

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation

2002 • 54 citations

Adjuvant therapy in colon cancer: current status and future directions

2002 • 49 citations

Induction of Multidrug Resistance Proteins MRP1 and MRP3 and γ-Glutamylcysteine Synthetase Gene Expression by Nonsteroidal Anti-inflammatory Drugs in Human Colon Cancer Cells

2002 • 46 citations

The Multidrug Resistance‐associated Protein Gene Confers Drug Resistance in Human Gastric and Colon Cancers

1996 • 39 citations

Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions.

2001 • 33 citations

Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance

1996 • 31 citations

An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells

1999 • 17 citations

Factors influencing the cellular accumulation of SN-38 and camptothecin

2002 • 17 citations

Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography

1995 • 12 citations

Introduction: genes, oncogenes, and gene therapy strategies for cancer.

1996 • 9 citations

Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.

1996 • 6 citations

Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography

1996 • 5 citations

Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-Ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography

2002 • 2 citations